Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abbisko Cayman's enterprise value is €439.39 Mil.
Abbisko Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-54.51 Mil. Therefore, Abbisko Cayman's EV-to-EBITDA for today is -8.06.
The historical rank and industry rank for Abbisko Cayman's EV-to-EBITDA or its related term are showing as below:
FRA:8ZD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.09 Med: 1.07 Max: 88.6
Current: -8.09
During the past 7 years, the highest EV-to-EBITDA of Abbisko Cayman was 88.60. The lowest was -8.09. And the median was 1.07.
FRA:8ZD's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.91
vs FRA:8ZD: -8.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbisko Cayman's PE Ratio (TTM) for today is calculated as:
Abbisko Cayman's share price for today is €0.965.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.093.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Abbisko Cayman's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8ZD vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Abbisko Cayman's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's EV-to-EBITDA falls into.
Abbisko Cayman's current Enterprise Value is €439.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-54.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (FRA:8ZD) has a EV-to-EBITDA of -8.06 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abbisko Cayman. According to the industry distribution chart, Abbisko Cayman ranks #999999 out of 402 companies in the Biotechnology industry.
Is Abbisko Cayman's EV-to-EBITDA too high?
Abbisko Cayman's current EV-to-EBITDA is -8.06. Based on the distribution chart, Abbisko Cayman ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abbisko Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #999999 out of 402 companies for EV-to-EBITDA. This places Abbisko Cayman in the lower half of its industry. The industry median EV-to-EBITDA is 13.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.91, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abbisko Cayman. For the Biotechnology industry, the median EV-to-EBITDA is 13.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current EV-to-EBITDA is -8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Abbisko Cayman (FRA:8ZD) has a current EV-to-EBITDA of -8.06. The stock's GF Value™ is €1.30, compared to a current price of €0.97 — trading 25.8% below its estimated fair value. The current EV-to-EBITDA is -8.06. Abbisko Cayman's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current EV-to-EBITDA is -8.06 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of €0.97 is trading 25.8% below its estimated GF Value™ of €1.30.
Key valuation signals for FRA:8ZD:
EV-to-EBITDA: -8.06
GF Value™: €1.30 vs. price of €0.97 (25.8% below fair value)
No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score
Get the complete analysis for FRA:8ZD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8ZD has been successfully added to your 
